Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. - Apostolova P; Kreutmair S; Toffalori C; Punta M; Unger S; Burk AC; Wehr C; Maas-Bauer K; Melchinger W; Haring E; Hoefflin R; Shoumariyeh K; et al. (British journal of haematology, 2023)